ゾダシランの第3相臨床試験（ヨセミテ試験）

基本情報

NCT ID

NCT07037771

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

60

治験依頼者名

Arrowhead Pharmaceuticals

概要

This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.

対象疾患

介入

依頼者（Sponsor）